Abstract
Historical progress in medicine can be charted along the lines of technical innovations that have visualized the invisible. One hundred years ago, Alois Alzheimer exploited newly developed histological stains to visualize his eponymonous disease in dead tissue under the microscope. Now, as we are entering the second century of Alzheimers disease research, technical innovation has endowed us with a range of in vivo imaging techniques that promise to visualize Alzheimer disease in living people. The earliest stage of Alzheimers disease is characterized by cell-sickness, not cell-death, and can occur before the deposition of amyloid plaques or neurofibrillary tangles. In principle, functional imaging techniques might be able to detect this early stage of the disease, a stage that was invisible to Alzheimer himself. Here, we will first define the neurobiological meaning of function and then review the different approaches that measure brain dysfunction in Alzheimer disease.
Keywords: Cerebral Blood Flow, SPECT, Deoxyhemoglobin, Glucose Uptake, synaptic strength, MRI
Current Alzheimer Research
Title: Imaging the Earliest Stages of Alzheimers Disease
Volume: 3 Issue: 5
Author(s): William Wu and Scott A. Small
Affiliation:
Keywords: Cerebral Blood Flow, SPECT, Deoxyhemoglobin, Glucose Uptake, synaptic strength, MRI
Abstract: Historical progress in medicine can be charted along the lines of technical innovations that have visualized the invisible. One hundred years ago, Alois Alzheimer exploited newly developed histological stains to visualize his eponymonous disease in dead tissue under the microscope. Now, as we are entering the second century of Alzheimers disease research, technical innovation has endowed us with a range of in vivo imaging techniques that promise to visualize Alzheimer disease in living people. The earliest stage of Alzheimers disease is characterized by cell-sickness, not cell-death, and can occur before the deposition of amyloid plaques or neurofibrillary tangles. In principle, functional imaging techniques might be able to detect this early stage of the disease, a stage that was invisible to Alzheimer himself. Here, we will first define the neurobiological meaning of function and then review the different approaches that measure brain dysfunction in Alzheimer disease.
Export Options
About this article
Cite this article as:
Wu William and Small A. Scott, Imaging the Earliest Stages of Alzheimers Disease, Current Alzheimer Research 2006; 3 (5) . https://dx.doi.org/10.2174/156720506779025161
DOI https://dx.doi.org/10.2174/156720506779025161 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Injured Cochlea as a Target for Inflammatory Processes, Initiation of Cell Death Pathways and Application of Related Otoprotective Strategies
Recent Patents on CNS Drug Discovery (Discontinued) Preface
Current Drug Targets - Infectious Disorders Immunoinformatic Approach for the Identification of Potential Epitopes Against <i>Stenotrophomonas maltophilia</i>: A Global Opportunistic Pathogen
Letters in Drug Design & Discovery Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry The Multifaceted Activities of Mammalian Defensins
Current Pharmaceutical Design Prokaryotic Substrate-Binding Proteins as Targets for Antimicrobial Therapies
Current Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design Relevance of Pharmacokinetic and Pharmacodynamic Modeling to Clinical Care of Critically Ill Patients
Current Pharmaceutical Biotechnology Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design N-Terminal Pro-C-Type Natriuretic Peptide: The Novel Marker in Selected Disease Units
Protein & Peptide Letters Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Brucella Pneumonia with Systemic Complications and Pancytopenia: A Case Report
Infectious Disorders - Drug Targets New Missions for an Old Agent: Granulocyte-Colony Stimulating Factor in the Treatment of Stroke Patients
Current Medicinal Chemistry